vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
15.85
-0.04 (-0.25%)
Jun 17, 2025, 4:00 PM - Market closed
vTv Therapeutics Revenue
vTv Therapeutics had revenue of $17.00K in the twelve months ending March 31, 2025, down -98.30% year-over-year. In the year 2024, vTv Therapeutics had annual revenue of $1.02M.
Revenue (ttm)
$17.00K
Revenue Growth
-98.30%
P/S Ratio
6,627.01
Revenue / Employee
$739
Employees
23
Market Cap
112.66M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
VTVT News
- 6 days ago - vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewsWire
- 4 weeks ago - vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin - GlobeNewsWire
- 4 weeks ago - vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes - GlobeNewsWire
- 3 months ago - vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges - Benzinga
- 3 months ago - vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes - GlobeNewsWire
- 6 months ago - CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER - PRNewsWire